1-6 of 6
David L. Russell-Jones
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes

Roselle A. Herring, Fariba Shojaee-Moradie, Mary Stevenage, Iain Parsons, Nicola Jackson, Jeewaka Mendis, Benita Middleton, A. Margot Umpleby, Barbara A. Fielding, Melanie Davies, David L. Russell-Jones
Journal: Diabetes Care
Diabetes Care 2022;45(6):1408–1415
https://doi.org/10.2337/dc21-2043
Published: 21 March 2022
View article titled, The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes
Open the PDF for The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes in another window
Journal Articles

Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136

Roselle A. Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A. Fielding, Agampodi Mendis, Sigurd Johnsen, A. Margot Umpleby, Melanie Davies, David L. Russell-Jones
Journal: Diabetes Care
Diabetes Care 2021;44(3):e61
https://doi.org/10.2337/dci20-0072
Published: 11 February 2021
View article titled, Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136
Open the PDF for Response to Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128–2136 in another window
Journal Articles

Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes

Roselle A. Herring, Fariba Shojaee-Moradie, Robert Garesse, Mary Stevenage, Nicola Jackson, Barbara A. Fielding, Agampodi Mendis, Sigurd Johnsen, A. Margot Umpleby, Melanie Davies, David L. Russell-Jones
Journal: Diabetes Care
Diabetes Care 2020;43(9):2128–2136
https://doi.org/10.2337/dc19-2579
Published: 08 July 2020
View article titled, Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes
Open the PDF for Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes in another window
Journal Articles

An Evaluation of the Safety of Pilots With Insulin-Treated Diabetes in Europe Flying Commercial and Noncommercial Aircraft

Gillian L. Garden, Julia L. Hine, Stuart J. Mitchell, Ewan J. Hutchison, Thomas P. Gaffney, Veronika Hofmann, Brian M. Frier, Kenneth M. Shaw, Simon R. Heller, Gerd Koehler, Graham A. Roberts, David L. Russell-Jones
Journal: Diabetes Care
Diabetes Care 2020;43(12):2923–2929
https://doi.org/10.2337/dc20-0277
Published: 25 June 2020
View article titled, An Evaluation of the Safety of Pilots With Insulin-Treated Diabetes in Europe Flying Commercial and Noncommercial Aircraft
Open the PDF for An Evaluation of the Safety of Pilots With Insulin-Treated Diabetes in Europe Flying Commercial and Noncommercial Aircraft in another window
Journal Articles

Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes

Sunil Zachariah, MRCP, Ben Sheldon, MRCP, Fariba Shojaee-Moradie, PHD, Nicola C. Jackson, PHD, Katharine Backhouse, PHD, Sigurd Johnsen, PHD, Richard H. Jones, FRCP, A. Margot Umpleby, PHD, David L. Russell-Jones, FRCP
Journal: Diabetes Care
Diabetes Care 2011;34(7):1487–1491
https://doi.org/10.2337/dc11-0098
Published: 17 June 2011
View article titled, Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes
Open the PDF for Insulin Detemir Reduces Weight Gain as a Result of Reduced Food Intake in Patients With Type 1 Diabetes in another window
Journal Articles

Intraperitoneal Insulin Affects Insulin-Like Growth Factor Binding Protein-1 in a Well-Controlled Type I Diabetic Patient

Kathleen D Hopkins, MD, David L Russell-Jones, MRCP, Eldon D Lehmann, BSC, Michael J Wheeler, PHD, Peter H Sönksen, FRCP
Journal: Diabetes Care
Diabetes Care 1993;16(10):1404–1405
https://doi.org/10.2337/diacare.16.10.1404
Published: 01 October 1993
View article titled, Intraperitoneal Insulin Affects Insulin-Like Growth Factor Binding Protein-1 in a Well-Controlled Type I Diabetic Patient
Open the PDF for Intraperitoneal Insulin Affects Insulin-Like Growth Factor Binding Protein-1 in a Well-Controlled Type I Diabetic Patient in another window